Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma

References

• AGIS InvestigatorsThe Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deteriorationAm J Ophthalmol200013042944011024415
   PubMed Web of Science ®Google Scholar
• GoldbergIClementCIChiangTHAssessing quality of life in patients with glaucoma using the Glaucoma Quality of Life-15 (GQL-15) questionnaireJ Glaucoma20091861219142128
   PubMed Web of Science ®Google Scholar
• BuronNMicheauOCathelinSDifferential mechanisms of conjunctival cell death induction by ultraviolet irradiation and benzalkonium chlorideInvest Ophthalmol Vis Sci2006474221423017003409
   PubMed Web of Science ®Google Scholar
• HopesMBroadwayDPreservative-free treatment in glaucoma is a sensible and realistic aim for the futureEuropean Ophthalmic Review201042328
   Google Scholar
• NoeckerREffects of common ophthalmic preservatives on ocular healthAdv Ther20011820521511783457
   PubMed Web of Science ®Google Scholar
• LempMAZimmermanLEToxic endothelial degeneration in ocular surface disease treated with topical medications containing benzalkonium chlorideAm J Ophthalmol198810566706733287942
   PubMed Web of Science ®Google Scholar
• RiegerGThe importance of the precorneal tear film for the quality of optical imagingBr J Ophthalmol1992761571581540559
   PubMed Web of Science ®Google Scholar
• AsbellPALempMADry Eye Disease: The Clinician’s Guide to Diagnosis and TreatmentNew York, NYThieme2006
   Google Scholar
• WidmaierEPRaffHStrangKTVander’s Human PhysiologyNew York, NYMcGraw-Hill200811108120
   Google Scholar
• SchaefferAJOsmotic pressure of the extraocular and intraocular fluidsArch Opthalmol19504310261035
   PubMedGoogle Scholar
• TomlinsonATear film osmolarity: determination of a referent for dry eye diagnosisInvest Ophthalmol Vis Sci2006474309431517003420
   PubMed Web of Science ®Google Scholar
• SullivanBDWhitmerDNicholsKKAn objective approach to dry eye disease severityInvest Ophthalmol Vis Sci2010516125623020631232
   PubMed Web of Science ®Google Scholar
• SuzukiMMassingaleMLFen YeFTear osmolarity as a biomarker for dry eye disease severityInvest Ophthalmol Vis Sci2010514557456120393114
   PubMed Web of Science ®Google Scholar
• FarrisRLTear osmolarity: a new gold standard?Adv Exp Med Biol19943504955038030524
   PubMedGoogle Scholar
• MastmannGJBaldesEJHendersonJWThe total osmotic pressure of tears in normal and various pathologic conditionsArch Ophthalmol19616550951313767987
   PubMedGoogle Scholar
• TerryJEHillRMHuman tear osmotic pressure: diurnal variations and the closed eyeArch Ophthalmol197896120122564175
   PubMedGoogle Scholar
• LiangHBaudouinCPaulyABrignole-BaudouinFConjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chlorideBr J Ophthalmol2008921275128218723745
   PubMed Web of Science ®Google Scholar
• BrasnuEBrignole-BaudouinFRianchoLGuenounJMWarnetJMBaudouinCIn vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell lineCurr Eye Res20083330331218398704
   PubMed Web of Science ®Google Scholar
• LempMAReport of the National Eye Institute/Industry Workshop on Clinical Trials in Dry EyesCLAO J1995212212328565190
   PubMedGoogle Scholar
• DranceSAndersonDRSchulzerMRisk factors for progression of visual field abnormalities in normal-tension glaucomaAm J Ophthalmol200113169970811384564
   PubMed Web of Science ®Google Scholar
• LeskeMCHeijlAHymanLPredictors of long-term progression in the early manifest glaucoma trialOphthalmology20071141965197217628686
   PubMed Web of Science ®Google Scholar
• KassMAHeuerDKHigginbothamEJThe Ocular Hypertension Treatment StudyA randomized trial determines that topical ocular hypertensive medication delays or prevents the onset of primary open-angle glaucomaArch Ophthalmol200212070171312049574
   PubMed Web of Science ®Google Scholar
• LeeDAHigginbothamEJGlaucoma and its treatment: a reviewAm J Health Syst Pharm20056269169915790795
   PubMed Web of Science ®Google Scholar
• BaudouinCAllergic reaction to topical eye-dropsCurr Opin Allergy Clin Immunol2005545946316131924
   PubMed Web of Science ®Google Scholar
• FisherAAAllergic contact dermatitis and conjunctivitis from benzalkonium chlorideCutis1987393813833581909
   PubMed Web of Science ®Google Scholar
• WhitsonJTCavanaghHDLakshmanNPetrollWMAssessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chlorideAdv Ther200623566367117142200
   PubMed Web of Science ®Google Scholar
• UusitaloHChenEPfeifferNSwitching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medicationActa Ophthalmologica20108832933620546237
   PubMed Web of Science ®Google Scholar
• MiyashiroMJLoSCStewartJAEfficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patientsClin Ophthalmol201041355135921179218
   PubMedGoogle Scholar
• LewisRAKatzGJWeissMJTravoprost BAC-free Study GroupTravoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacyJ Glaucoma2007169810317224758
   PubMed Web of Science ®Google Scholar
• HamacherTAiraksinenJSaarelaVEfficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysisActa Ophthalmol Suppl (Oxf)2008242141918752510
   PubMedGoogle Scholar
• LempMABronAJBaudouinCTear osmolarity in the diagnosis and management of dry eye diseaseAm J Ophthalmol201115179279821310379
   PubMed Web of Science ®Google Scholar
• LuoLLiDQPflugfelderSCHyperosmolarity-induced apoptosis in human corneal epithelial cells is mediated by cytochrome c and MAPK pathwaysCornea20072645246017457195
   PubMed Web of Science ®Google Scholar
• LeungEWMedeirosFAWeinrebRNPrevalence of ocular surface disease in glaucoma patientsJ Glaucoma20081735035518703943
   PubMed Web of Science ®Google Scholar
• MillerKLWaltJGMinkDRMinimal clinically important difference for the ocular surface disease indexArch Ophthalmol20101289410120065224
   PubMed Web of Science ®Google Scholar
• SchiffmanRChristiansonMDJacobsenGHirschJDReisBLReliability and validity of the ocular surface disease indexArch Ophthalmol200011861562110815152
   PubMed Web of Science ®Google Scholar
• FechtnerRDGodfreyDGBudenzDStewartJAStewartWCJasekMCPrevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medicationsCornea20102961862120386433
   PubMed Web of Science ®Google Scholar
• BaudouinCDetrimental effect of preservatives in eye-drops: implications for the treatment of glaucomaActa Ophthalmol20088671672618537937
   PubMed Web of Science ®Google Scholar
• PisellaPJPouliquenPBaudouinCPrevalence of ocular symptoms and signs with preserved and preservative free glaucoma medicationBr J Ophthalmol20028641842311914211
   PubMed Web of Science ®Google Scholar